Home > Publications Database > German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson's disease: new spotlights on diagnostic procedures and non-pharmacological interventions. > print

001     275853
005     20250113165814.0
024 7 _ |a 10.1007/s00415-024-12503-0
|2 doi
024 7 _ |a pmid:39120709
|2 pmid
024 7 _ |a pmc:PMC11561078
|2 pmc
024 7 _ |a 0367-004X
|2 ISSN
024 7 _ |a 0012-1037
|2 ISSN
024 7 _ |a 0340-5354
|2 ISSN
024 7 _ |a 1432-1459
|2 ISSN
037 _ _ |a DZNE-2025-00088
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kalbe, Elke
|0 0000-0001-8603-2545
|b 0
245 _ _ |a German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson's disease: new spotlights on diagnostic procedures and non-pharmacological interventions.
260 _ _ |a [Darmstadt]
|c 2024
|b Steinkopff
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1736767537_1045
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cognitive impairment and dementia as well as affective disorders are common and debilitating syndromes that develop in people with Parkinson's disease (PwPD). The authors summarized recommendations for the 2023 updated German guidelines on 'Parkinson's disease' from the German Neurological Society (DGN), focusing on the diagnosis and treatment of these disorders.The recommendations were based on literature reviews, other relevant guidelines, and expert opinions.Measurements to assess cognitive and affective states were reviewed for psychometric properties, use in routine clinical practice, and availability in German. To improve mild cognitive impairment, cognitive training and physical aerobic training are recommended. To treat Parkinson's disease (PD)-related dementia, cognitive stimulation (as a non-pharmacological intervention) and acetylcholinesterase inhibitors (AChEIs, i.e., rivastigmine) are recommended. Cognitive behavioral therapy is recommended to treat depression, anxiety, and fear of progression. Physical interventions are recommended to treat depression, fatigue, and apathy. Optimized dopaminergic treatment is the first-line pharmacological strategy recommended to manage depression, apathy, anhedonia, fatigue, and mood swings. Major depression can be additionally treated using venlafaxine or desipramine, while moderate depression can be treated pharmacologically according to its clinical phenotype (psychomotor retardation or agitation) and comorbidities (e.g., sleep disturbances, pain). Venlafaxine and nortriptyline can be used to treat anhedonia, while citalopram can be used for anxiety.In addition to the updated pharmacological treatment options, new insights into recommendations for standardized diagnostics and non-pharmacological interventions were provided for the German health care system. However, more studies are needed to explore the full potential of non-pharmacological interventions to treat and prevent cognitive impairment and affective disorders.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Anxiety
|2 Other
650 _ 7 |a Dementia
|2 Other
650 _ 7 |a Depression
|2 Other
650 _ 7 |a Guideline
|2 Other
650 _ 7 |a Mild cognitive impairment
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: etiology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: therapy
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnosis
|2 MeSH
650 _ 2 |a Germany
|2 MeSH
650 _ 2 |a Mood Disorders: etiology
|2 MeSH
650 _ 2 |a Mood Disorders: therapy
|2 MeSH
650 _ 2 |a Mood Disorders: diagnosis
|2 MeSH
650 _ 2 |a Neurology: standards
|2 MeSH
650 _ 2 |a Parkinson Disease: complications
|2 MeSH
650 _ 2 |a Parkinson Disease: therapy
|2 MeSH
650 _ 2 |a Parkinson Disease: diagnosis
|2 MeSH
650 _ 2 |a Practice Guidelines as Topic: standards
|2 MeSH
650 _ 2 |a Societies, Medical: standards
|2 MeSH
650 _ 2 |a Review Literature as Topic
|2 MeSH
700 1 _ |a Folkerts, Ann-Kristin
|0 0000-0003-2168-140X
|b 1
700 1 _ |a Witt, Karsten
|0 0000-0002-9384-3474
|b 2
700 1 _ |a Buhmann, Carsten
|0 0000-0001-8540-3789
|b 3
700 1 _ |a Liepelt-Scarfone, Inga
|0 P:(DE-2719)2109499
|b 4
700 1 _ |a Group, German Parkinson’s Guidelines
|b 5
|e Collaboration Author
773 _ _ |a 10.1007/s00415-024-12503-0
|g Vol. 271, no. 11, p. 7330 - 7357
|0 PERI:(DE-600)1421299-7
|n 11
|p 7330 - 7357
|t Journal of neurology
|v 271
|y 2024
|x 0367-004X
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/275853/files/DZNE-2025-00088.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/275853/files/DZNE-2025-00088.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:275853
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2109499
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-10
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-10
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-10
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-10
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21